AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2008
Mar 18, 2008
31801_dirs_2008-03-17_0c6f2e72-fdb3-4b2f-a717-5706dd26a4ca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2008-03-07
Reporting Person: PAREKH RAJESH R (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, par value $0.001 per share | 56223 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $8.16 | 2018-03-07 | Common Stock (17879) | Direct |
Footnotes
F1: An entity owned in part by Dr. Rajesh B. Parekh and his spouse is entitled to receive 56,223 shares of common stock, par value $0.001 per share (the "Shares") of AVANT Immunotherapeutics, Inc upon the planned liquidation of Lorantis Holdings Limited during 2008. Mr. Parekh disclaims beneficial ownership of these Shares and is not involved in any decision making with respect to the disposition of these Shares.
F2: As of March 7, 2008 (the "Effective Date"), Dr. Rajesh B. Parekh beneficially owns options to purchase 17,879 Shares. Options to purchase 11,368 Shares are exercisable as of the Effective Date. Options to purchase 6,511 Shares will be exercisable on the six-month anniversary of the Effective Date.